The Epidemiological Investigation And Clinical Observation Of XXXX01 For The Treatment Of The Rash Caused By EGFR-TKIs In NSCLC

Objective: 1.To investigate the incidence of rash during the EGFR-TKIs treatment of non-small cell lung cancer in respiratory department of Northern Jiangsu People's Hospital from 2016 to 2018.Explore the relationship of sex,age,different target drugs,pathological type of tumor or gene mutation site with the incidence or severity of rash;2.To evaluate the clinical therapeutic effect of the external ointment XXXX01 for the treatment of EGFR-TKIs-induced rash in 56 cases.Methods: 1.Collected relevant information(including name,sex,age,pathological type,tumor stage,gene mutation site,etc.)of 171 non-small cell lung cancer patients in the respiratory department of Northern Jiangsu People's Hospital from 2016 to 2018.Telephone-outpatient follow-up and medical records follow-up were performed on patients for information about rashes,targeted drug use,later treatment,and disease progression,and the incidence of rash was counted.2.56 cases of advanced NSCLC patients with skin rash after EGFR-TKIs treatment were admitted as treatment group.At the same time,general information(including name,sex,age,pathological type,tumor stage,drug use,etc.)and rash information were registered and photographed.The patients were treated with external skin rash prevention and treatment,twice a day.The patients were followed up once a week.Recorded and photographed when the rash was obviously relieved.After 1 and 3 months,the patients were visited back to collect the information about the rash,the therapeutic effect and the photography.Results:1.The total incidence of skin rash in non-small cell lung cancer patients treated with EGFR-TKIs was 53.2% and the incidence of severe rash was 8.2%.The incidence of grade 1 rash was the highest(32.20%).The incidences of rash in gefitinib group and icotinib were 61.7% and 30.2%,respectively,among which,the rates of severe rash were 10.2% and 2.3%,respectively.There was a significant difference between the two drugs(P < 0.05),and there was also a significant difference in the incidence of different grade rash between the two drugs(P < 0.05),The incidence of EGFR-TKIs-associated rash in female was higher than that in male,but the pathological type and tumor score were significantly higher than those in male(P < 0.05).There was no significant difference in the incidence of rash among pathological type,tumor stage,age,age or mutation sites(P > 0.05).2.A total of 56 patients were enrolled in the treatment group.After EGFR-TKIs treatment,the cure rate was 26.8%,the total effective rate was 80.4%,the three-month cure rate was 60.7% and the total effective rate was 92.9%.There was no significant difference in the effective rate between the two groups(P > 0.05).Conclusion: 1.The total incidence of rash and severe rash were 53.2% and 8.2% respectively.There was a significant difference in the incidence of rashes between patients with different EGFR-TKIs and sexes(P < 0 05).The incidence of rashes in NSCLC treated with gefitinib was higher than that in NSCLC treated with icotinib.The incidence of rash in female patients was higher than that in male patients.But there was no significant difference among pathological types,tumor stages,age and mutation sites(P > 0.05).2.The total effective rate of 1 month and 3 months was 80.4% and 92.9% respectively.There was no significant difference(P > 0.05)in the treatment effect of External ointment of XXXX01 in gefitinib group and icotinib group.(P > 0.05).